Tetradentate ligands are used to form neutral 99m-technetium complexes which may be useful as radiopharmaceuticals e.g. as brain imaging agents. The ligands have the structure ##STR1## where n is 2 or 3, m is 0-4, R is H or substituted or unsubstituted C.sub.1 -C.sub.6 alkyl, provided that one CR.sub.2 group adjacent the starred nitrogen atom represents CO and forms with the adjacent N atom, a --CONH-- amide group, Y is unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, and one of X and X' represents H or a labile thiol protecting group while the other is unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, alkenyl or alkynyl.
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.
